| Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction TA of the Safety The Lancet 358 (9282), 605-613, 2001 | 400 | 2001 |
| DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment R Villani, A Facciorusso, F Bellanti, R Tamborra, A Piscazzi, ... PloS one 11 (12), e0167934, 2016 | 136 | 2016 |
| Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis F Bellanti, R Villani, A Facciorusso, G Vendemiale, G Serviddio Free Radical Biology and Medicine 111, 173-185, 2017 | 133 | 2017 |
| From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases T Cassano, R Villani, L Pace, A Carbone, VN Bukke, S Orkisz, C Avolio, ... Frontiers in pharmacology 11, 124, 2020 | 132 | 2020 |
| Lipid metabolism in development and progression of hepatocellular carcinoma M Sangineto, R Villani, F Cavallone, A Romano, D Loizzi, G Serviddio Cancers 12 (6), 1419, 2020 | 119 | 2020 |
| Modulation of the oxidative stress and lipid peroxidation by endocannabinoids and their lipid analogues CA Gallelli, S Calcagnini, A Romano, JB Koczwara, M De Ceglia, D Dante, ... Antioxidants 7 (7), 93, 2018 | 99 | 2018 |
| The dual role of glutamatergic neurotransmission in Alzheimer’s disease: From pathophysiology to pharmacotherapy VN Bukke, M Archana, R Villani, AD Romano, A Wawrzyniak, ... International journal of molecular sciences 21 (20), 7452, 2020 | 87 | 2020 |
| Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials A Facciorusso, F Bellanti, R Villani, V Salvatore, N Muscatiello, ... United European gastroenterology journal 5 (4), 511-518, 2017 | 86 | 2017 |
| Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in … R Lombardi, L Airaghi, G Targher, G Serviddio, G Maffi, A Mantovani, ... Liver international 40 (2), 347-354, 2020 | 81 | 2020 |
| Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis V Sapena, M Enea, F Torres, C Celsa, J Rios, GEM Rizzo, P Nahon, ... Gut 71 (3), 593-604, 2022 | 80 | 2022 |
| Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression F Bellanti, R Villani, R Tamborra, M Blonda, G Iannelli, G di Bello, ... Redox biology 15, 86-96, 2018 | 75 | 2018 |
| Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal A Romano, G Serviddio, S Calcagnini, R Villani, AM Giudetti, T Cassano, ... Free Radical Biology and Medicine 111, 281-293, 2017 | 73 | 2017 |
| Alterations of clock gene RNA expression in brain regions of a triple transgenic model of Alzheimer’s disease F Bellanti, G Iannelli, M Blonda, R Tamborra, R Villani, A Romano, ... Journal of Alzheimer's Disease 59 (2), 615-631, 2017 | 70 | 2017 |
| Effects of dietary fatty acids and cholesterol excess on liver injury: A lipidomic approach G Serviddio, F Bellanti, R Villani, R Tamborra, C Zerbinati, M Blonda, ... Redox Biology 9, 296-305, 2016 | 54 | 2016 |
| Immunity as cornerstone of non-alcoholic fatty liver disease: the contribution of oxidative stress in the disease progression M Dallio, M Sangineto, M Romeo, R Villani, AD Romano, C Loguercio, ... International journal of molecular sciences 22 (1), 436, 2021 | 51 | 2021 |
| Assessing the impact of COVID-19 on liver cancer management (CERO-19) S Muñoz-Martínez, V Sapena, A Forner, JC Nault, G Sapisochin, ... JHEP reports 3 (3), 100260, 2021 | 48 | 2021 |
| Pharmacological treatment of depression in Alzheimer’s disease: a challenging task T Cassano, S Calcagnini, A Carbone, VN Bukke, S Orkisz, R Villani, ... Frontiers in pharmacology 10, 1067, 2019 | 47 | 2019 |
| Molecular mechanisms involved in HCC recurrence after direct-acting antiviral therapy R Villani, G Vendemiale, G Serviddio International Journal of Molecular Sciences 20 (1), 49, 2018 | 47 | 2018 |
| <? covid19?> Tocilizumab and liver injury in patients with COVID-19 G Serviddio, R Villani, G Stallone, G Scioscia, MP Foschino-Barbaro, ... Therapeutic Advances in Gastroenterology 13, 1756284820959183, 2020 | 42 | 2020 |
| Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis A Facciorusso, N Tartaglia, R Villani, G Serviddio, D Ramai, BP Mohan, ... American Journal of Translational Research 13 (4), 2379, 2021 | 37 | 2021 |
Gaetano Serviddiouniversità di Foggia在 unifg.it 的电子邮件经过验证
